PHARMALEX
PHARMALEX, a leading global provider of regulatory affairs, quality assurance, and compliance services, is headquartered in Great Britain. Founded in 1998, the company has established a strong presence across Europe, North America, and Asia, catering to the pharmaceutical, biotechnology, and medical device industries. With a focus on delivering tailored solutions, PHARMALEX offers a comprehensive range of services, including clinical trial management, market access strategies, and post-market surveillance. Their commitment to quality and regulatory excellence has positioned them as a trusted partner for clients navigating complex compliance landscapes. Recognised for their innovative approach and industry expertise, PHARMALEX continues to achieve significant milestones, solidifying their reputation as a key player in the life sciences sector.
DitchCarbon Score
How does PHARMALEX's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
PHARMALEX's score of 36 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
PHARMALEX's reported carbon emissions
In 2021, PHARMALEX reported total carbon emissions of approximately 1,487,150 kg CO2e. This figure includes emissions across all three scopes: Scope 1 emissions were about 27,080 kg CO2e, Scope 2 emissions totalled approximately 97,560 kg CO2e, and Scope 3 emissions accounted for a significant 1,416,510 kg CO2e. Notably, the largest contributors to Scope 3 emissions were purchased goods and services, which represented about 1,007,000 kg CO2e, followed by employee commute at approximately 333,000 kg CO2e and business travel at around 62,000 kg CO2e. Despite the detailed emissions reporting, PHARMALEX has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of formal climate commitments or science-based targets suggests that while the company is aware of its emissions profile, it may not yet have established a comprehensive strategy for emissions reduction. As the industry increasingly prioritises sustainability, PHARMALEX's future climate commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 27,080 |
| Scope 2 | 97,560 |
| Scope 3 | 1,416,510 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PHARMALEX is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
